HPRL
MCID: HYP020
MIFTS: 64

Hyperprolactinemia (HPRL)

Categories: Blood diseases, Endocrine diseases, Genetic diseases, Metabolic diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Hyperprolactinemia

MalaCards integrated aliases for Hyperprolactinemia:

Name: Hyperprolactinemia 57 12 76 75 37 29 55 6 44 15 73
Chiari-Frommel Syndrome 12 53 44 73
Hprl 57 75
Familial Isolated Prolactin Receptor Deficiency 59
Pregnancy-Related a-G Syndrome 12
Familial Hyperprolactinemia 59
Chiarifrommel Syndrome 76
Hyperprolactinaemia 12
Hyperprolactinemia, 40

Characteristics:

Orphanet epidemiological data:

59
familial hyperprolactinemia
Inheritance: Autosomal dominant; Age of onset: Adult;

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
hyperprolactinemia:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 57 615555
Disease Ontology 12 DOID:12700
ICD10 33 E22.1
NCIt 50 C113168
SNOMED-CT 68 21170004 85039006
Orphanet 59 ORPHA397685
ICD10 via Orphanet 34 E22.1
MedGen 42 C0020514
KEGG 37 H01388

Summaries for Hyperprolactinemia

OMIM : 57 Hyperprolactinemia unrelated to pregnancy occurs in approximately 0.1 to 0.3% of the general population and may result in infertility, hypogonadism, and galactorrhea. Such nonphysiologic hyperprolactinemia is caused mainly by drugs or by tumors in the anterior pituitary gland, primarily prolactinomas (see 102200). However, 10 to 60% of patients with hyperprolactinemia who undergo MRI have normal findings (summary by Newey et al., 2013). (615555)

MalaCards based summary : Hyperprolactinemia, also known as chiari-frommel syndrome, is related to mccune-albright syndrome and galactorrhea. An important gene associated with Hyperprolactinemia is PRLR (Prolactin Receptor), and among its related pathways/superpathways are PI3K-Akt signaling pathway and JAK-STAT signaling pathway. The drugs Aripiprazole and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include pituitary, ovary and bone, and related phenotypes are osteopenia and osteoporosis

Disease Ontology : 12 An acquired metabolic disease that has material basis in the presence of abnormally-high levels of prolactin in the blood.

UniProtKB/Swiss-Prot : 75 Hyperprolactinemia: A disorder characterized by increased levels of prolactin in the blood not associated with gestation or the puerperium. HPRL may result in infertility, hypogonadism, and galactorrhea.

Wikipedia : 76 Hyperprolactinaemia or hyperprolactinemia is the presence of abnormally high levels of prolactin in the... more...

Related Diseases for Hyperprolactinemia

Diseases related to Hyperprolactinemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 278)
# Related Disease Score Top Affiliating Genes
1 mccune-albright syndrome 32.0 GH1 IGF1 PRL SST
2 galactorrhea 30.8 DRD2 IGF1 PRL PRLR
3 amenorrhea 30.4 GNRH1 POMC PRL SHBG TRH
4 gigantism 30.4 GH1 PRL
5 impotence 30.2 PRL SHBG VIP
6 peripartum cardiomyopathy 30.2 DRD2 PRL
7 precocious puberty 30.2 GH1 GNRH1
8 infertility 30.2 GNRH1 H19 PRL PRLR
9 polycystic ovary syndrome 30.1 GNRH1 IGF1 PRL SHBG
10 pituitary tumors 30.1 GH1 IGF1 POMC PRL SST
11 hypothyroidism 30.0 GH1 IGF1 POMC PRL SHBG TRH
12 gynecomastia 30.0 POMC PRL SHBG
13 abducens nerve disease 30.0 POMC PRL
14 adenoma 30.0 GH1 IGF1 POMC PRL SST
15 acromegaly 29.9 GH1 IGF1 POMC PRL SST TRH
16 ovarian disease 29.9 GNRH1 IGF1 PRL SHBG
17 hypopituitarism 29.8 GH1 GNRH1 IGF1 POMC PRL
18 lymphocytic hypophysitis 29.8 GH1 POMC
19 central precocious puberty 29.7 GNRH1 IGF1
20 anovulation 29.7 GNRH1 IGF1 PRL SHBG
21 non-functioning pituitary adenoma 29.7 GH1 SST
22 tetrahydrobiopterin deficiency 29.7 GH1 PRL
23 fasting hypoglycemia 29.7 IGF1 POMC
24 bipolar disorder 29.7 DRD2 IGF1 PRL SHBG
25 pituitary gland disease 29.6 GH1 GNRH1 IGF1 POMC PRL SST
26 sheehan syndrome 29.6 IGF1 POMC PRL
27 multiple endocrine neoplasia, type i 29.6 PRL SST VIP
28 fibrous dysplasia 29.6 GH1 IGF1 PRL SST
29 empty sella syndrome 29.6 GH1 GNRH1 IGF1 POMC PRL TRH
30 fibromyalgia 29.5 IGF1 PRL
31 premature ovarian failure 1 29.5 GNRH1 PRL SHBG
32 hyperandrogenism 29.5 GNRH1 IGF1 POMC PRL SHBG
33 hypothalamic disease 29.5 GH1 GNRH1 POMC PRL
34 tsh producing pituitary tumor 29.5 GH1 GNRH1 POMC PRL SST
35 breast disease 29.4 IGF1 POMC PRL PRLR SHBG
36 osteoporosis 29.4 GH1 IGF1 PTHLH SHBG
37 conn's syndrome 29.4 GH1 POMC PRL SST
38 hyperthyroidism 29.4 GH1 PRL SHBG SST TRH
39 chiasmal syndrome 29.4 GNRH1 POMC PRL SST
40 craniopharyngioma 29.3 GH1 GNRH1 IGF1 PRL TRH
41 insulin-like growth factor i 29.3 GH1 IGF1 PRL SHBG SST
42 functioning pituitary adenoma 29.1 DRD2 GH1 POMC PRL SST TRH
43 breast cancer 29.0 GNRH1 H19 IGF1 PRL PRLR PTHLH
44 pituitary adenoma, prolactin-secreting 28.8 DRD2 GH1 IGF1 POMC PRL SST
45 galactorrhoea-hyperprolactinaemia 11.6
46 amenorrhea-galactorrhea syndrome 11.6
47 ahumada del castillo syndrome 11.1
48 schizophrenia 10.4
49 fibrous dysplasia/mccune-albright syndrome 10.3 GH1 PRL
50 generalized resistance to thyroid hormone 10.3 PRL TRH

Graphical network of the top 20 diseases related to Hyperprolactinemia:



Diseases related to Hyperprolactinemia

Symptoms & Phenotypes for Hyperprolactinemia

Symptoms via clinical synopsis from OMIM:

57
Genitourinary Internal Genitalia Female:
infertility (in some patients)
oligomenorrhea (in some patients)
menorrhagia (in some patients)

Chest Breasts:
galactorrhea (in some patients)

Endocrine Features:
elevated prolactin levels


Clinical features from OMIM:

615555

Human phenotypes related to Hyperprolactinemia:

59 32 (show all 10)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 osteopenia 59 32 occasional (7.5%) Occasional (29-5%) HP:0000938
2 osteoporosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000939
3 infertility 59 32 occasional (7.5%) Frequent (79-30%) HP:0000789
4 menorrhagia 59 32 occasional (7.5%) Occasional (29-5%) HP:0000132
5 galactorrhea 59 32 occasional (7.5%) Very frequent (99-80%) HP:0100829
6 female hypogonadism 59 32 occasional (7.5%) Occasional (29-5%) HP:0000134
7 amenorrhea 59 32 frequent (33%) Frequent (79-30%) HP:0000141
8 oligomenorrhea 59 32 occasional (7.5%) Very frequent (99-80%) HP:0000876
9 hemorrhagic ovarian cyst 59 32 frequent (33%) Frequent (79-30%) HP:0012886
10 prolactin excess 32 HP:0000870

MGI Mouse Phenotypes related to Hyperprolactinemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.07 DRD2 GNRH1 IGF1 POMC PRL PRLR
2 endocrine/exocrine gland MP:0005379 10.06 DRD2 GNRH1 IGF1 POMC PRL PRLR
3 immune system MP:0005387 9.92 DRD2 GNRH1 IGF1 POMC PRL PTHLH
4 adipose tissue MP:0005375 9.83 DRD2 IGF1 POMC PRLR PTHLH
5 integument MP:0010771 9.8 DRD2 GNRH1 IGF1 POMC PRL PRLR
6 neoplasm MP:0002006 9.7 DRD2 GNRH1 IGF1 POMC PRL PRLR
7 nervous system MP:0003631 9.61 DRD2 GNRH1 IGF1 POMC PRL PRLR
8 reproductive system MP:0005389 9.17 DRD2 GNRH1 IGF1 PRL PRLR PTHLH

Drugs & Therapeutics for Hyperprolactinemia

Drugs for Hyperprolactinemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 107)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aripiprazole Approved, Investigational Phase 4,Not Applicable 129722-12-9 60795
2
Dopamine Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 51-61-6, 62-31-7 681
3
Risperidone Approved, Investigational Phase 4,Phase 3,Not Applicable 106266-06-2 5073
4
Cabergoline Approved Phase 4,Not Applicable 81409-90-7 54746
5
Quinagolide Approved, Investigational Phase 4 97805-50-0, 87056-78-8 105105
6
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
7
Polyestradiol phosphate Approved Phase 4 28014-46-2
8 Estradiol valerate Approved, Investigational, Vet_approved Phase 4 979-32-8
9
Amantadine Approved Phase 4 768-94-5 2130
10 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Not Applicable
11 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Not Applicable
12 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Not Applicable
13 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable
14 Serotonin 5-HT2 Receptor Antagonists Phase 4
15 Dopamine D2 Receptor Antagonists Phase 4
16 Paliperidone Palmitate Phase 4
17 Dopamine Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
18 Serotonin Agents Phase 4,Phase 3,Not Applicable
19 Dopamine Antagonists Phase 4,Phase 3,Not Applicable
20 Serotonin Antagonists Phase 4,Phase 3,Not Applicable
21 Neurotransmitter Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
22 Dopamine agonists Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
23 Antiparkinson Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
24 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Peripheral Nervous System Agents Phase 4,Phase 1,Phase 2
26 Estradiol 17 beta-cypionate Phase 4
27 Estradiol 3-benzoate Phase 4
28 Anti-Infective Agents Phase 4
29 Antiviral Agents Phase 4
30 Analgesics Phase 4
31 Analgesics, Non-Narcotic Phase 4
32
Serotonin Investigational, Nutraceutical Phase 4,Phase 3,Not Applicable 50-67-9 5202
33
Bromocriptine Approved, Investigational Phase 3 25614-03-3 31101
34
Calcium Carbonate Approved, Investigational Phase 3 471-34-1
35
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
36
Ergocalciferol Approved, Nutraceutical Phase 3 50-14-6 5280793
37 Hormone Antagonists Phase 3,Phase 2
38 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
39 Calciferol Phase 3
40 Trace Elements Phase 3
41 Antacids Phase 3
42 Micronutrients Phase 3
43 Calcium, Dietary Phase 3,Phase 2
44 Ergocalciferols Phase 3
45 Anti-Ulcer Agents Phase 3
46 Vitamin D2 Phase 3
47 Vitamins Phase 3
48 Gastrointestinal Agents Phase 3
49 Bone Density Conservation Agents Phase 3
50 Quetiapine Fumarate Phase 3 111974-72-2

Interventional clinical trials:

(show all 44)
# Name Status NCT ID Phase Drugs
1 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia Unknown status NCT00541554 Phase 4 Abilify (aripiprazole)
2 A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum Disorders Unknown status NCT01742390 Phase 4 Aripiprazole;risperidone or paliperidone
3 High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone Unknown status NCT00539071 Phase 4 long-acting injectable risperidone;long acting injectable risperidone;long acting injectable risperidone
4 Aripiprazole and Prolactin Study Completed NCT01085383 Phase 4 Aripiprazole
5 Endometriosis Patients Undergoing Quinagolide Treatment Completed NCT00625950 Phase 4
6 Color Doppler Analysıs Of Uterin And Intraovarian Blood Flow Before And After Treatment Wıth Cabergoline In Hyperprolactinemic Patients Completed NCT01957839 Phase 4 cabergoline treatment
7 A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children Completed NCT01050582 Phase 4 Risperidone;Other atypical antipsychotic drugs
8 The Luveris In Vitro Fertilization Trial Terminated NCT00889512 Phase 4 Luveris fixed dose;Luveris increasing dose
9 Study of Amantadine for Risperidone Consta or Paliperidone Treated Patients to Decrease Prolactin Elevation Terminated NCT00975611 Phase 4 Amantadine Hydrochloride, USP;Amantadine Hydrochloride, USP;Placebo
10 Risperidone-Induced Hyperprolactinemia Treated With Bromocriptine Unknown status NCT00315081 Phase 3 Bromocriptin
11 Calcium and Vitamin D to Optimize Bone Mass in Boys With Risperidone-induced Hyperprolactinemia Completed NCT00799383 Phase 3 Calcium and Vitamin D
12 Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to Risperidone Completed NCT00600756 Phase 3 Quetiapine XR;Risperidone
13 Peony-Glycyrrhiza Decoction (PGD) for Antipsychotic-induced Hyperprolactinemia in Patients With Schizophrenia Completed NCT01852331 Phase 2 PGD granules;Placebo
14 Administration of Kisspeptin in Patients With Hyperprolactinemia Recruiting NCT02956447 Phase 2 Kisspeptin 112-121;Gonadotropin Releasing Hormone (GnRH)
15 Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole Recruiting NCT03038308 Phase 1, Phase 2 Ropinirole
16 Effectiveness and Safety of Bushen Culuan Decoction for Anovulatory Infertility Not yet recruiting NCT03709849 Phase 2 experimental group: Bushen Culuan Decoction and Clomiphene Citrate Tablets placebo;control group: Clomiphene Citrate Tablets and Bushen Culuan Decoction placebo
17 Administration of Kisspeptin to Subjects With Reproductive Disorders Recruiting NCT00914823 Phase 1 kisspeptin 112-121;GnRH
18 Adjunctive Aripiprazole in the Treatment of Risperidone-Induced Hyperprolactinemia Unknown status NCT02013232 Not Applicable Aripiprazole
19 Efficacy of Rapid Escalation of Cabergoline in Comparison to Conventional Dosing in Prolactin Secreting Macroadenomas. Unknown status NCT01143584 Not Applicable Cabergoline;cabergoline
20 TSH And AMH in Infertile Women Unknown status NCT02710175
21 Hyperprolactinaemia Management in Reproductive Services at University Hospital of Coventry and Warwickshire Completed NCT03569787
22 Changes in Hyperprolactinemia Secondary to Antipsychotics After Switching to Quetiapine Completed NCT00952757
23 Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia Completed NCT01338298 Not Applicable Aripiprazole;Placebo
24 Characterization of Macroprolactinemia Completed NCT00436111
25 The Relationship of PRL and Polycystic Ovary Syndrome (PCOS) in Taiwan's Women Completed NCT01117272
26 Study On Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE) Completed NCT01270711 Study Drug
27 Mathematical Model for the Human Menstrual Cycle, Endocrinological Diseases and Fertility Treatment-PAEON Completed NCT02098668
28 The Association Between Dopamine Agonists and Cardiac Valvulopathy, Fibrosis and Other Cardiopulmonary Events Completed NCT01052948
29 The Effect of Monoclonal Vascular Endothelial Growth Factor (VEGF) Antibody (Bevacizumab) on Pituitary Function Completed NCT00973557
30 Bone Mineral Content and Bone Metabolism in Adolescents on Antipsychotic Therapy Completed NCT00399776
31 Post-Authorization Safety Surveillance Study of Asenapine in Participants With Bipolar Disorder (P08307) Completed NCT01495741
32 Comparison of Bone Mineral Density Changes During Tx With Risperidone or Aripiprazole in Adolescents Completed NCT00573716
33 Prevalence of Pregnancy in Polycystic Ovary Syndrome Completed NCT03157921
34 Calcium Homeostasis in Acromegaly: Effect of Surgical/Medical Treatment and Comparison With Nonfunctioning Pituitary Tumors Completed NCT01568359
35 Cardiac Valve Complications in Prolactinomas Treated With Cabergoline Completed NCT00460616 Cabergoline
36 Insulin Resistance in Women With Prolactinoma Completed NCT00481299
37 Effects of Hyperprolactinemia Induced by Antipsychotic Drugs on Bone Metabolism Recruiting NCT03675750
38 Radial Shockwave Therapy for Erectile Dysfunction Recruiting NCT03596047 Not Applicable
39 Seoul National University Pituitary Disease Cohort Study Recruiting NCT03474601
40 Pituitary Histopathology and Hyperprolactinaemia and Risk of Glucose Metabolic Disturbances in Acromegaly. Active, not recruiting NCT02092129
41 Pituitary Function and Spontaneous Intracranial Hypotension Active, not recruiting NCT02603549
42 Assessing Fertility Potential in Female Cancer Survivors Active, not recruiting NCT01143844
43 Effects of Exercise and Yogurt on Bone Mineral Density and Immunological Factors in Human Milk: The MEEMA Study Not yet recruiting NCT03732261 Not Applicable
44 Substrate Metabolism and Insulin Sensitivity in Patients With Hyperprolactinemia Before and After Treatment Withdrawn NCT00699530

Search NIH Clinical Center for Hyperprolactinemia

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: hyperprolactinemia

Genetic Tests for Hyperprolactinemia

Genetic tests related to Hyperprolactinemia:

# Genetic test Affiliating Genes
1 Hyperprolactinemia 29 PRLR

Anatomical Context for Hyperprolactinemia

MalaCards organs/tissues related to Hyperprolactinemia:

41
Pituitary, Ovary, Bone, Testes, Endothelial, Breast, Thyroid

Publications for Hyperprolactinemia

Articles related to Hyperprolactinemia:

(show top 50) (show all 1166)
# Title Authors Year
1
Using domperidone to induce and sustain hyperprolactinemia in late-pregnant gilts. ( 30205268 )
2019
2
Combined Cabergoline and Metformin in Patients with Polycystic Ovarian Disease with Hyperprolactinemia: Methodological Concerns. ( 29896007 )
2018
3
Hyperprolactinemia as a Side Effect of Long-Acting Injectable Risperidone Therapy or a Symptom of Klinefelter Syndrome - a Diagnostic and Therapeutic Dilemma. ( 29546865 )
2018
4
Prevalence and risk factors of hyperprolactinemia among patients with various psychiatric diagnoses and medications. ( 29334291 )
2018
5
A Comment on "Add-on Aripiprazole for Atypical Antipsychotic-induced, Clinically Significant Hyperprolactinemia". ( 29875544 )
2018
6
Metabolic Syndrome in Hyperprolactinemia. ( 29894997 )
2018
7
The effect of bromocriptine treatment on sexual functioning and depressive symptoms in women with mild hyperprolactinemia. ( 29475005 )
2018
8
Frequency of Macroprolactin in Hyperprolactinemia. ( 29394965 )
2018
9
Dopamine agonist withdrawal in hyperprolactinemia: when and how. ( 29124662 )
2018
10
Primary Amenorrhea Associated with Hyperprolactinemia in Polyglandular Autoimmune Syndrome Type II: A Case Report. ( 29949817 )
2018
11
Interpretation of serum gonadotropin levels in hyperprolactinemia. ( 29660734 )
2018
12
Short-Term Hyperprolactinemia Reduces the Expression of Purinergic P2X7 Receptors during Allergic Inflammatory Response of the Lungs. ( 29874677 )
2018
13
Hyperprolactinemia-inducing antipsychotics increase breast cancer risk by activating JAK-STAT5 in precancerous lesions. ( 29778097 )
2018
14
Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis. ( 29043560 )
2018
15
Controversial issues in the management of hyperprolactinemia and prolactinomas - An overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism. ( 29768629 )
2018
16
Add-on Aripiprazole for Atypical Antipsychotic-induced, Clinically Significant Hyperprolactinemia. ( 29403128 )
2018
17
Hyperprolactinemia with Galactorrhea Due to Subclinical Hypothyroidism: A Case Report and Review of Literature. ( 30079289 )
2018
18
The effects of hyperprolactinemia and its control on metabolic diseases. ( 30058862 )
2018
19
Hyperprolactinemia and insulin resistance in drug naive patients with early onset first episode psychosis. ( 30068291 )
2018
20
Treatment of Risperidone-Associated Hyperprolactinemia With Aripiprazole. ( 30106879 )
2018
21
Different Effects of Atorvastatin on Cardiometabolic Risk Factors in Young Women With and Without Hyperprolactinemia. ( 30129670 )
2018
22
Clinical and Radiographic Characteristics Related to Hyperprolactinemia in Nonfunctioning Pituitary Adenomas. ( 30144593 )
2018
23
A real-world analysis of healthcare costs and relative risk of hyperprolactinemia associated with antipsychotic treatments in the United States. ( 30188234 )
2018
24
Management of antipsychotic related hyperprolactinemia in older people: Can we extrapolate from existing guidance? ( 30216566 )
2018
25
Idiopathic Hyperprolactinemia Presenting as Polycystic Ovary Syndrome in Identical Twin Sisters: A Case Report and Literature Review. ( 30250766 )
2018
26
Hyperprolactinemia / Prolactinomas in the post-menopausal period: <br><br>challenges in diagnosis and management <br><br>. ( 30347396 )
2018
27
Clinical and Laboratory Characteristics of Hyperprolactinemia in Children and Adolescents: National Survey. ( 30396878 )
2018
28
Psychological effects of Dopamine Agonist Treatment in Patients with Hyperprolactinemia and Prolactin Secreting Adenomas. ( 30400048 )
2018
29
Different effects of fenofibrate on cardiometabolic risk factors in young women with and without hyperprolactinemia. ( 30469130 )
2018
30
Laboratory and clinical significance of macroprolactinemia in women with hyperprolactinemia. ( 29241908 )
2017
31
Occurrence of hyperprolactinemia in children with subclinical hypothyroidism. ( 28529200 )
2017
32
Hyperprolactinemia Induced by Antipsychotics: From Diagnosis to Treatment Approach. ( 28440197 )
2017
33
Adjunctive metformin for antipsychotic-related hyperprolactinemia: A meta-analysis of randomized controlled trials. ( 28372526 )
2017
34
Efficacy of Combined Cabergoline and Metformin Compared to Metformin Alone on Cycle Regularity in Patients with Polycystic Ovarian Disease with Hyperprolactinemia: A Randomized Clinical Trial. ( 28867888 )
2017
35
Calcium and Vitamin D Supplementation in Boys with Risperidone-Induced Hyperprolactinemia: A Randomized, Placebo-Controlled Pilot Study. ( 29112461 )
2017
36
Myocardial Recovery in Peripartum Cardiomyopathy After Hyperprolactinemia Treatment on BIVAD. ( 27748657 )
2017
37
Risperidone Induced Granulomatous Mastitis Secondary to Hyperprolactinemia in a Non-Pregnant Woman-A Rare Case Report in a Bipolar Disorder. ( 28273980 )
2017
38
Serum prolactin revisited: parametric reference intervals and cross platform evaluation of polyethylene glycol precipitation-based methods for discrimination between hyperprolactinemia and macroprolactinemia. ( 28236625 )
2017
39
Vasculogenic hyperprolactinemia: severe prolactin excess in association with internal carotid artery aneurysms. ( 28828544 )
2017
40
The central mechanism of risperidone-induced hyperprolactinemia. ( 28336493 )
2017
41
Paeoniflorin and liquiritin, two major constituents in Chinese herbal formulas used to treat hyperprolactinemia-associated disorders, inhibits prolactin secretion in prolactinoma cells by different mechanisms. ( 28396166 )
2017
42
Long-Term Follow-Up of Primary Medical Versus Surgical Treatment of Prolactinomas in Men: Effects on Hyperprolactinemia, Hypogonadism, and Bone Health. ( 27773859 )
2017
43
Hyperprolactinemia with low dose of risperidone in a young female. ( 28558899 )
2017
44
Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics. ( 28235557 )
2017
45
Re: Myocardial Recovery in Peripartum Cardiomyopathy after Hyperprolactinemia Treatment on Biventricular Assist Device. ( 28114195 )
2017
46
Therapeutic effects of Schisandra chinensis on the hyperprolactinemia in rat. ( 28259983 )
2017
47
Cabergoline for hyperprolactinemia: getting to the heart of it. ( 28260205 )
2017
48
An Intact Dopamine Sensitivity in the Brain: A Necessity to Recover Hyperprolactinemia and Galactorrhea in a Female Hemodialysis Patient? ( 28791188 )
2017
49
Time Course of Resolution of Hyperprolactinemia After Transsphenoidal Surgery Among Patients Presenting with Pituitary Stalk Compression. ( 27671881 )
2017
50
Hyperprolactinemia and the Association with All-Cause Mortality and Cardiovascular Mortality. ( 28437810 )
2017

Variations for Hyperprolactinemia

UniProtKB/Swiss-Prot genetic disease variations for Hyperprolactinemia:

75
# Symbol AA change Variation ID SNP ID
1 PRLR p.His212Arg VAR_070895 rs398122522

ClinVar genetic disease variations for Hyperprolactinemia:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 PRLR NM_001204316.1(PRLR): c.635A> G (p.His212Arg) single nucleotide variant Pathogenic rs398122522 GRCh37 Chromosome 5, 35070276: 35070276
2 PRLR NM_001204316.1(PRLR): c.635A> G (p.His212Arg) single nucleotide variant Pathogenic rs398122522 GRCh38 Chromosome 5, 35070174: 35070174

Expression for Hyperprolactinemia

Search GEO for disease gene expression data for Hyperprolactinemia.

Pathways for Hyperprolactinemia

Pathways related to Hyperprolactinemia according to KEGG:

37
# Name Kegg Source Accession
1 PI3K-Akt signaling pathway hsa04151
2 JAK-STAT signaling pathway hsa04630
3 Prolactin signaling pathway hsa04917

GO Terms for Hyperprolactinemia

Cellular components related to Hyperprolactinemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 GH1 GNRH1 IGF1 POMC PRL PTHLH
2 perikaryon GO:0043204 9.5 DRD2 GNRH1 VIP
3 secretory granule GO:0030141 9.43 POMC PRL TRH
4 extracellular region GO:0005576 9.36 GH1 GNRH1 IGF1 POMC PRL PRLR
5 endosome lumen GO:0031904 9.13 GH1 PRL PRLR

Biological processes related to Hyperprolactinemia according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 9.87 DRD2 GNRH1 POMC PTHLH SST TRH
2 positive regulation of cell proliferation GO:0008284 9.86 IGF1 PRL PTHLH VIP
3 negative regulation of cell proliferation GO:0008285 9.78 DRD2 GNRH1 PTHLH SST
4 response to organic cyclic compound GO:0014070 9.63 GNRH1 PRL TRH
5 female pregnancy GO:0007565 9.58 GNRH1 PRL PTHLH
6 response to ethanol GO:0045471 9.56 DRD2 GNRH1 PRL TRH
7 adult walking behavior GO:0007628 9.55 DRD2 TRH
8 cell-cell signaling GO:0007267 9.55 GNRH1 POMC PTHLH SST TRH
9 response to steroid hormone GO:0048545 9.54 GNRH1 SST
10 regulation of multicellular organism growth GO:0040014 9.52 IGF1 PRL
11 positive regulation of JAK-STAT cascade GO:0046427 9.51 GH1 PRL
12 positive regulation of receptor internalization GO:0002092 9.49 DRD2 GH1
13 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.43 GH1 IGF1
14 ovulation cycle GO:0042698 9.37 GNRH1 PRL
15 regulation of signaling receptor activity GO:0010469 9.28 GH1 GNRH1 IGF1 POMC PRL PTHLH
16 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.13 GH1 PRL PRLR

Molecular functions related to Hyperprolactinemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.28 GH1 GNRH1 IGF1 POMC PRL PTHLH
2 peptide hormone receptor binding GO:0051428 9.16 PTHLH VIP
3 prolactin receptor binding GO:0005148 8.96 GH1 PRL

Sources for Hyperprolactinemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....